Allogeneic bone marrow transplantation for systemic AL amyloidosis

British Journal of Haematology

Volumn 100, Issue 1, 1998, Pages 226-228

  Gillmore, Julian D ^a   Davies, John ^b   Iqbal, Adil ^c   Madhoo, Sheril ^a   Russell, Nigel H ^c   Hawkins, Philip N ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^c NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Allogeneic transplantation; Amyloid; Amyloidosis; Bone marrow transplantation; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISONE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; AMYLOIDOSIS; ARTICLE; CAPILLARY RESISTANCE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; HUMAN; MACROGLOSSIA; MALE; PRIORITY JOURNAL; TREATMENT FAILURE; WHOLE BODY RADIATION;

AMYLOIDOSIS; BONE MARROW TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 0031961761     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1998.00527.x     Document Type: Article

References (12)

1. Bjorkstrand, B., Ljungman, P. & Svensson, H. (1996) Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective casematched study from the European Group for Blood and Marrow Transplantation. Blood, 88, 4711.
2. Comenzo, R.L., Falk, R.H., Simms, R.W., Vosburgh, E. & Skinner, M. (1996) I.v. melphalan with blood stem-cell rescue for AL amyloidosis: a two year experience. Arthritis and Rheumatism, 39, S1 32.
3. Corradini, P., Tarella, C., Voena, C., Astolfi, M., Ladetto, M., Palumbo, A., Santoro, A., Majolino, I., Bacigulpo, A., Pileri, A. & Boccadoro, M. (1997) PCR-based monitoring of residual myeloma cells in patients undergoing high-dose chemotherapy. In: VI International Workshop on Multiple Myeloma (ed. by K. Anderson). Harvard Medical School, Boston, Mass.
4. Gertz, M.A., Kyle, R.A. & Greipp, P.R. (1991) Response rates and survival in primary systemic amyloidosis. Blood, 77, 257-262.
5. Hawkins, P.N. (1994) Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo. Clinical Science, 87, 289-295.
6. 123I-labeled serum amyloid P component. New England Journal of Medicine, 323, 508-513.
7. Kyle, R. & Gertz, M.A. (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Haematology, 32, 45-59.
8. Kyle, R., Gertz, M., Greipp, P., Witzig, T., Lust, J., Lacy, M. & Therneau, T (1997) A trial of three regimes for primary amyloidosis: colchicine alone, melphalan and prednisolone, and melphalan, prednisolone and colchicine. New England Journal of Medicine, 336, 1202-1207.
9. Mehta, J., Nagler, A. & Slavin, S. (1992) Marrow transplantation in multiple myeloma. New England Journal of Medicine, 326, 1087.
10. Persey, M.R., Lovat, L.B., Apperley, J.F., Madhoo, S., Pepys, M.B. & Hawkins, P.N. (1996) Intensive chemotherapy for AL amyloidosis. British Journal of Rheumatology, 35, (Suppl. 1), 12.
11. Tan, S.Y., Pepys, M.B., Hawkins, P.N. (1995) Treatment of amyloidosis. American Journal of Kidney Diseases, 26, 267-285.
12. Van Buren, M., Hene, R.J., Verdonck, L.F., Verzijlbergen, F.J. & Lokhorst, H.M. (1995) Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Annals of Internal Medicine, 122, 672-678.